Τίτλος:
The use of radiolabeled somatostatin analog scintigraphy in the staging
of small cell lung cancer patients
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Objectives: The prognosis of patients with small cell lung cancer (SCLC)
is dismal with a median survival not exceeding 18 months. For the fact
that the tumor stage remains the most significant prognostic factor,
efforts have been made to improve its accuracy. We evaluated the role of
somatostatin receptor scintigraphy (SRS) in the diagnosis and initial
staging of SCLC in comparison with the conventional staging procedure.
Methods: We administered radiolabeled somatostatin analog Indium 111
(111 In)-diethylenetriamine pentaacetic acid (also known as Indium In-
111 pentetreotide or OctreoScan) in 32 newly diagnosed patients with
SCLC, 19 of which of had limited disease and 13 of which had extensive
disease. All patients had been previously examined with other imaging
modalities, specifically CT and/or MRI.
Results: Staging with 111 In- OctreoScan successfully located the
primary tumor site with a sensitivity of 92%. Although detection of
mediastinal lymph node dissemination was also relatively high (83%),
the SRS failed to detect most of the metastatic lesions outside the
thorax (9 of 36, 25%), while its sensitivity for the detection of
malignant lesions in the liver, adrenals, and bones, was 56%, 33% and
17%, respectively.
Conclusions: Although 111 In-OctreoScan may be used in addition to
current SCLC staging methods, there are insufficient data for
maintaining that SRS may replace conventional staging.
Συγγραφείς:
Tzannou, Ifigeneia A.
Karapanagiotou, Eleni M.
Charpidou,
Adrianni
Dilana, Kalliopi
Alamara, Christina and
Christakopoulou, Ioanna
Georgiou, Evangelos
Syrigos,
Konstantinos N.
Περιοδικό:
AMERICAN JOURNAL OF CLINICAL ONCOLOGY - CANCER CLINICAL TRIALS
Εκδότης:
Lippincott, Williams & Wilkins
Λέξεις-κλειδιά:
octreotide; scintigraphy; lung cancer; staging; receptors
DOI:
10.1097/COC.0b013e3180546747
